Note: This document contains side effect information about isavuconazonium. Some of the dosage forms listed on this page may not apply to the brand name Cresemba.
Common side effects of Cresemba include: dyspnea, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, and increased serum bilirubin. Other side effects include: hypotension. See below for a comprehensive list of adverse effects.
Applies to isavuconazonium: oral capsule
Other dosage forms:
Along with its needed effects, isavuconazonium (the active ingredient contained in Cresemba) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking isavuconazonium:
Less common or rare
Incidence not known
Some side effects of isavuconazonium may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common or rare
Applies to isavuconazonium: intravenous powder for injection, oral capsule
The most common side effects were nausea, vomiting, diarrhea, headache, elevated liver chemistry tests, hypokalemia, constipation, dyspnea, cough, peripheral edema, and back pain. Serious side effects were reported in 55% of patients. Therapy was permanently discontinued due to side effects in 14% of patients; confusional state, acute renal failure, increased blood bilirubin, convulsion, dyspnea, epilepsy, respiratory failure, and vomiting led to permanent discontinuation most often.
Very common (10% or more): Nausea (up to 27.6%), vomiting (up to 25%), diarrhea (up to 23.7%), abdominal pain (16.7%), constipation (up to 14%)
Common (1% to 10%): Dyspepsia
Frequency not reported: Abdominal distension, gastritis, gingivitis, stomatitis
Very common (10% or more): Hypokalemia (up to 19.1%)
Common (1% to 10%): Decreased appetite, hypomagnesemia
Frequency not reported: Hypoalbuminemia, hypoglycemia, hyponatremia
Elevated liver transaminases (ALT or AST) greater than 3 times the upper limit of normal (3 x ULN) and greater than 10 x ULN were reported in 4.4% and 1.2% of patients, respectively.
Very common (10% or more): Elevated liver chemistry/laboratory tests (includes increased ALT, AST, blood alkaline phosphatase, blood bilirubin, GGT; up to 17.1%)
Common (1% to 10%): Elevated liver transaminases (ALT or AST)
Frequency not reported: Cholecystitis, cholelithiasis, hepatitis, hepatomegaly, hepatic failure, cholestasis
Very common (10% or more): Dyspnea (up to 17.1%), cough (12%)
Common (1% to 10%): Acute respiratory failure
Frequency not reported: Bronchospasm, tachypnea
Very common (10% or more): Headache (up to 17%)
Frequency not reported: Convulsion, epilepsy, dysgeusia, encephalopathy, hypoesthesia, migraine, peripheral neuropathy, paresthesia, somnolence, stupor, syncope, tremor, tinnitus, vertigo
Very common (10% or more): Peripheral edema (up to 15.2%), fatigue (10.5%)
Common (1% to 10%): Chest pain
Frequency not reported: Infusion-related reactions (including hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia), catheter thrombosis, malaise, chills, fall
Very common (10% or more): Insomnia (10.5%)
Common (1% to 10%): Delirium (includes agitation, confusional state, delirium, disorientation, mental status changes), anxiety
Frequency not reported: Confusion, hallucination, depression
Very common (10% or more): Renal failure (10.1%)
Frequency not reported: Acute renal failure
Very common (10% or more): Back pain (up to 10.1%)
Frequency not reported: Myositis, bone pain, neck pain
Common (1% to 10%): Hypotension
Frequency not reported: Atrial fibrillation, atrial flutter, bradycardia, reduced QT interval on ECG, palpitations, supraventricular extrasystoles, supraventricular tachycardia, ventricular extrasystoles, cardiac arrest, thrombophlebitis
Common (1% to 10%): Rash, pruritus
Frequency not reported: Alopecia, dermatitis, exfoliative dermatitis, erythema, petechiae, urticaria
Common (1% to 10%): Injection site reaction
Frequency not reported: Agranulocytosis, leukopenia, pancytopenia
Frequency not reported: Hypersensitivity
Frequency not reported: Hematuria, proteinuria
Frequency not reported: Optic neuropathy
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Cresemba